Header Logo

Connection

WOLFGANG WINKELMAYER to Hematinics

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Hematinics.
WOLFGANG WINKELMAYER
Connection Strength
6.892
Hematinics
  1. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. Am J Kidney Dis. 2017 Jun; 69(6):771-779.
    View in: PubMed
    Score: 0.532
  2. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
    View in: PubMed
    Score: 0.474
  3. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
    View in: PubMed
    Score: 0.465
  4. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
    View in: PubMed
    Score: 0.442
  5. Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis. 2013 Dec; 62(6):1217-20.
    View in: PubMed
    Score: 0.430
  6. Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol. 2011 Jul; 6(7):1794-801.
    View in: PubMed
    Score: 0.363
  7. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011 Jan; 22(1):1-2.
    View in: PubMed
    Score: 0.350
  8. The challenges of cost-effectiveness analyses for the clinician. Am J Kidney Dis. 2010 Dec; 56(6):1023-5.
    View in: PubMed
    Score: 0.349
  9. On the relative safety of intravenous iron formulations: new answers, new questions. Am J Hematol. 2010 Sep; 85(9):643-4.
    View in: PubMed
    Score: 0.343
  10. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010 Mar 03; 303(9):857-64.
    View in: PubMed
    Score: 0.331
  11. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
    View in: PubMed
    Score: 0.212
  12. Market Competition and Anemia Management in the United States Following Dialysis Payment Reform. Med Care. 2023 Nov 01; 61(11):787-795.
    View in: PubMed
    Score: 0.212
  13. Iron Sucrose and Blood Pressure Patterns During Hemodialysis. Am J Kidney Dis. 2023 06; 81(6):629-631.
    View in: PubMed
    Score: 0.205
  14. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
    View in: PubMed
    Score: 0.200
  15. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
    View in: PubMed
    Score: 0.195
  16. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
    View in: PubMed
    Score: 0.186
  17. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
    View in: PubMed
    Score: 0.179
  18. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
    View in: PubMed
    Score: 0.179
  19. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021 06; 99(6):1280-1295.
    View in: PubMed
    Score: 0.179
  20. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol. 2016 Oct; 27(10):3129-3138.
    View in: PubMed
    Score: 0.125
  21. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related?Quality of Life in Patients Receiving?Hemodialysis. Am J Kidney Dis. 2016 Feb; 67(2):271-82.
    View in: PubMed
    Score: 0.122
  22. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients. Am J Kidney Dis. 2016 Jan; 67(1):119-27.
    View in: PubMed
    Score: 0.122
  23. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2068-75.
    View in: PubMed
    Score: 0.121
  24. IV iron dosing regimens: choice of agent and dosing frequency. Nephrol News Issues. 2014 Feb; 28(2):10-1, 18.
    View in: PubMed
    Score: 0.109
  25. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol. 2012 Sep; 78(3):181-8.
    View in: PubMed
    Score: 0.098
  26. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
    View in: PubMed
    Score: 0.080
  27. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep; 54(3):554-60.
    View in: PubMed
    Score: 0.079
  28. No associations between prolactin concentrations and response to erythropoiesis-stimulating agents in hemodialysis patients. Am J Nephrol. 2007; 27(4):390-6.
    View in: PubMed
    Score: 0.069
  29. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004 Oct; 66(4):1712; author reply 1712-3.
    View in: PubMed
    Score: 0.057
  30. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol. 2000 Jun; 11(6):1106-1116.
    View in: PubMed
    Score: 0.042
  31. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019 Jun; 22(6):593-604.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.